Topics

Articles

A deeper commitment to oncology and immunology

Cellular and genetic therapies (CGTs) developers are struggling to build capacity

Oncology represents half of the dollar volume of HDA-member sales

Pfizer’s Ibrance was the star performer from the class of 2015 FDA approvals

Sales volume handled by primary wholesaler/distributors seems to be declining

HFAP builds out from its hospital-accreditation business

Already-built Las Colinas facility will be the global headquarters in April 2019

Most pharmacists want more time to counsel patients; most are concerned with drug reimbursement issues

Billions of dollars are at stake with analyzing and optimizing GTN decisions

PBM squares the circle by offering a lower drug price—where some payers wouldn’t want it